The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Kazuhiro Yoshida
Honoraria - Amco; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; MSD K.K; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Yasuhiro Kodera
Honoraria - Abbvie; Amgen; Bristol Myers Squibb; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Abbvie (Inst); Bayer (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TOA Pharmaceuticals (Inst); Tsumura & Co. (Inst)
 
Masato Kitazawa
No Relationships to Disclose
 
Motohiro Hirao
No Relationships to Disclose
 
Yasuyuki Seto
No Relationships to Disclose
 
Kenji Hibi
No Relationships to Disclose
 
Shinichi Kinami
No Relationships to Disclose
 
Masaya Watanabe
No Relationships to Disclose
 
Shigeto Makino
No Relationships to Disclose
 
Mitsugu Kochi
No Relationships to Disclose
 
Takeshi Sano
Speakers' Bureau - Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoshihiro Kakeji
Honoraria - Taiho Pharmaceutical
 
Masahiro Takeuchi
No Relationships to Disclose
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization